Latest filing published 01 Jun 2026 for Edesa Biotech, Inc..
This profile gathers the share dealings of Michael Brooks in Edesa Biotech, Inc. Between 6 November 2020 and 27 May 2026, the trades on record add up to 13 filings.
Purchases make up the whole of the open-market record (9 purchases, €48k). Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Besides market trades, the filings include 1 share grant and 1 option exercise. In 2026 alone, the filings show 1 purchase and no sales.
The median purchase comes to €3,331. No cluster: in 9 purchases, no other insider of the company bought within 30 days.
On 1 June 2026 came the latest disclosure, a share grant in Edesa Biotech, Inc. The latest purchase dates back some time: it was published 227 days ago, on 11 March 2026. The median gap between a trade and its publication by SEC (Form 4) is 4 days. Section 16 rules allow two business days to file each Form 4. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
13 of 13 declarations